The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Aclaris Therapeutics, Inc. COM 00461U105   19,235,033 2,808,034 SH   SOLE   2,808,034 0 0
Cymabay Therapeutics, Inc. COM 23257D103   26,645,572 1,787,094 SH   SOLE   1,787,094 0 0
Kinnate Biopharma Inc. COM 49705R105   13,540,300 9,671,643 SH   SOLE   9,671,643 0 0
Kura Oncology, Inc. COM 50127T109   16,871,517 1,849,947 SH   SOLE   1,849,947 0 0
Lyell Immunopharma, Inc. COM 55083R104   12,913,675 8,784,813 SH   SOLE   8,784,813 0 0
Pharvaris N.V. COM N69605108   78,125,802 3,743,450 SH   SOLE   3,743,450 0 0
Syndax Pharmaceuticals, Inc. COM 87164F105   12,705,000 875,000 SH   SOLE   875,000 0 0